These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9035091)

  • 21. FDA flexes muscle in oversight of medical devices, technologies.
    Cruise C
    Biomed Instrum Technol; 2011; 45(2):105-8. PubMed ID: 21466325
    [No Abstract]   [Full Text] [Related]  

  • 22. Electoral campaign delays resolution of biotech issues.
    Fox JL
    Nat Biotechnol; 2004 Oct; 22(10):1193. PubMed ID: 15470439
    [No Abstract]   [Full Text] [Related]  

  • 23. Substantial equivalence: its uses and abuses.
    Miller HI
    Nat Biotechnol; 1999 Nov; 17(11):1042-3. PubMed ID: 10545866
    [No Abstract]   [Full Text] [Related]  

  • 24. Biotechnology. EPA proposal would exempt some GMOs from registry.
    Reardon S
    Science; 2011 May; 332(6030):652. PubMed ID: 21551040
    [No Abstract]   [Full Text] [Related]  

  • 25. Off-label drug use.
    Dooley AG
    Med Health R I; 2007 Feb; 90(2):63-5. PubMed ID: 17500258
    [No Abstract]   [Full Text] [Related]  

  • 26. US agbio controversies continue.
    Fox JL
    Nat Biotechnol; 1999 Jul; 17(7):628. PubMed ID: 10409343
    [No Abstract]   [Full Text] [Related]  

  • 27. FDA targets unapproved drugs.
    Young D
    Am J Health Syst Pharm; 2007 Feb; 64(4):347-8. PubMed ID: 17299170
    [No Abstract]   [Full Text] [Related]  

  • 28. Off-label prescribing. Legal implications.
    Henry V
    J Leg Med; 1999 Sep; 20(3):365-83. PubMed ID: 10530051
    [No Abstract]   [Full Text] [Related]  

  • 29. A much-anticipated FDA reform bill is signed into law: progress and compromise.
    Nissen SE
    Curr Cardiol Rep; 2008 Feb; 10(1):1-2. PubMed ID: 18416992
    [No Abstract]   [Full Text] [Related]  

  • 30. BIO and biogenerics.
    Feldbaum CB
    Nat Biotechnol; 2005 Jan; 23(1):17; discussion 17. PubMed ID: 15637607
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy of labeling of foods and pharmaceuticals.
    Viscusi WK
    Annu Rev Public Health; 1994; 15():325-43. PubMed ID: 8054088
    [No Abstract]   [Full Text] [Related]  

  • 32. Speed and oversight: FDA Commissioner Gottlieb acts on pledges.
    Morrison C
    Nat Biotechnol; 2017 Oct; 35(10):898-899. PubMed ID: 29019996
    [No Abstract]   [Full Text] [Related]  

  • 33. [Not Available].
    Kuchuk N
    Tsitol Genet; 2017; 51(2):40-6. PubMed ID: 30484617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What ails the FDA?
    Okie S
    N Engl J Med; 2005 Mar; 352(11):1063-6. PubMed ID: 15784660
    [No Abstract]   [Full Text] [Related]  

  • 35. Big news for plant transformation.
    Michelmore R
    Nat Biotechnol; 1996 Dec; 14(13):1653-4. PubMed ID: 9634844
    [No Abstract]   [Full Text] [Related]  

  • 36. Overdue process.
    Nat Biotechnol; 2004 Nov; 22(11):1329. PubMed ID: 15529137
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmaceuticals and medical devices: FDA oversight.
    Berry MD
    Issue Brief Health Policy Track Serv; 2013 Dec; ():1-123. PubMed ID: 24482893
    [No Abstract]   [Full Text] [Related]  

  • 38. Investing in risk management.
    Fiscus PW
    Nat Biotechnol; 1997 Jan; 15(1):88-9. PubMed ID: 9035113
    [No Abstract]   [Full Text] [Related]  

  • 39. Turning plants into protein factories.
    Fox JL
    Nat Biotechnol; 2006 Oct; 24(10):1191-3. PubMed ID: 17033647
    [No Abstract]   [Full Text] [Related]  

  • 40. US lawmakers tackle safety reforms at the FDA.
    Zwillich T
    Lancet; 2007 Jun; 369(9578):1989-90. PubMed ID: 17577942
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.